Results from a phase 3 trial showed that the combination of Nubeqa, docetaxel and androgen-deprivation therapy significantly decreased the risk of death for men with a certain type of prostate cancer.
Improved screening to reduce over diagnosis and over treatment of prostate cancer
Insurance company contributed to settlement without insured’s consent.
Click to read findings of Weill Cornell Medicine, published March 22 in the Journal of the National Cancer Institute.
Genetic determinants of PSA proved to robustly predict prostate cancer diagnoses and improve the detection of aggressive disease; however, larger and more diverse studies are still required.
Read this perspective shared by a prostate cancer survivor